← Back to Patent Explorer
US4252790A Expired / Lapsed US ⏱️ 0.0 years remaining

Method for treating gastric ulcer-prone patients

Assignee: Interx Research Corp
•
Filing: 1974-10-23
•
Granted: 1981-02-24
•
Expires: 1994-10-23
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Gastric ulcer-prone patients are treated by introducing into the stomach thereof an effective amount of a non-toxic, non-absorbable active agent, preferably an anion exchange resin having strong hydrophobic binding tendencies (e.g., a styrene-divinylbenzene copolymer bearing quaternary ammonium functional groups), or a hydrophobic, nonionic polymeric adsorbent, capable of effectively binding free and conjugated bile acids present in the stomach as a result of duodenogastric regurgitation.

Inventors

  • 👤 Takeru Higuchi

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-02 08:36
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/74; A61K33/00

Claims Analysis

Total Claims: 18
Claim 1
Independent Claim 118 words
A method for treating gastric ulcers in a patient afflicted with pyloric incompetence and concomitant duodenogastric regurgitation of bile acids, which method comprises periodically co-administering into the stomach of such patient (1) an effective, bile acid conjugating amount of a non-toxic, non-absorbable resinous active agent capable of effectively binding the free and conjugated bile acids present in the stomach as a result of said duodenogastric regurgitation, said resinous active agent being a hydrophobic, styrene-divinylbenzene copolymer anion exchange resin bearing quaternary ammonium functional groups, together with (2) a bile acid buffering amount of a pharmaceutically acceptable alkalizer; and whereby there is thus counteracted the elevated level of such gastric bile acids in the stomach caused by said pyloric incompetence.
Claim 2
Independent Claim 118 words
A method for treating gastric ulcers in a patient afflicted with pyloric incompetence and concomitant duodenogastric regurgitation of bile acids, which method comprises periodically co-administering into the stomach of such patient (1) an effective, bile acid conjugating amount of a non-toxic, non-absorbable resinous active agent capable of effectively binding the free and conjugated bile acids present in the stomach as a result of said duodenogastric regurgitation, said resinous active agent being a hydrophobic, styrene-divinylbenzene copolymer anion exchange resin bearing quaternary ammonium functional groups, together with (2) a bile acid buffering amount of a pharmaceutically acceptable alkalizer; and whereby there is thus counteracted the elevated level of such gastric bile acids in the stomach caused by said pyloric incompetence.
Claim 3
Independent Claim 115 words
A method for treating gastric ulcers in a patient afflicted with pyloric incompetence and concomitant duodenogastric regurgitation of bile acids, which method comprises periodically co-administering into the stomach of such patient (1) an effective, bile acid conjugating amount of a non-toxic, non-absorbable resinous active agent capable of effectively binding the free and conjugated bile acids present in the stomach as a result of said duodenogastric regurgitation, said resinous active agent being a hydrophobic, cholestyramine anion exchange resin, together with (2) a bile acid buffering amount of a pharmaceutically acceptable aluminum hydroxide gel alkalizer; and whereby there is thus counteracted the elevated level of such gastric bile acids in the stomach caused by said pyloric incompetence.
Claim 4
Independent Claim 115 words
A method for treating gastric ulcers in a patient afflicted with pyloric incompetence and concomitant duodenogastric regurgitation of bile acids, which method comprises periodically co-administering into the stomach of such patient (1) an effective, bile acid conjugating amount of a non-toxic, non-absorbable resinous active agent capable of effectively binding the free and conjugated bile acids present in the stomach as a result of said duodenogastric regurgitation, said resinous active agent being a hydrophobic, cholestyramine anion exchange resin, together with (2) a bile acid buffering amount of a pharmaceutically acceptable aluminum hydroxide gel alkalizer; and whereby there is thus counteracted the elevated level of such gastric bile acids in the stomach caused by said pyloric incompetence.
Claim 5
Dependent Claim 22 words
The method of claim 1, wherein from 25 to 500 mgs. of said active agent are co-administered into the stomach per dose.
Claim 6
Dependent Claim 15 words
The method of claim 1, wherein said active agent is orally co-administered into the stomach.
Claim 7
Dependent Claim 13 words
The method of claim 4, wherein said active agent is in tablet form.
Claim 8
Dependent Claim 22 words
The method of claim 1, wherein from 2,000 to 8,000 mgs. of said active agent are co-administered into the stomach per day.
Claim 9
Dependent Claim 14 words
The method of claim 4, wherein said active agent is formulated in liquid form.
Claim 10
Dependent Claim 40 words
The method of claim 1, wherein said pharmaceutically acceptable alkalizer is a member selected from the group consisting of sodium bicarbonate, milk of magnesia, calcium carbonate, an aluminum hydroxide gel, a sulphated magnesium hydroxy aluminate, a silicate, and mixtures thereof.
Claim 11
Dependent Claim 30 words
The method of claim 1, wherein the effective amount of active agent is co-administered into the stomach during a period when the ulcerogenic effect of refluxing bile acids is enhanced.
Claim 12
Dependent Claim 11 words
The method of claim 1, wherein said patient is gastric ulcer-prone.
Claim 13
Dependent Claim 110 words
A pharmaceutical composition for the treatment of gastric ulcers in a patient afflicted with pyloric incompetence and concomitant duodenogastric regurgitation of bile acids, and suited for regulating the regurgitation of duodenal contents into the stomach, said composition essentially consisting of a unit dosage formulation of (1) an effective, bile acid conjugating amount of a non-toxic, non-absorbable resinous active agent capable of effectively binding the free and conjugated bile acids present in the stomach as a result of said duodenogastric regurgitation, said resinous active agent being a hydrophobic, styrene-divinyl-benzene copolymer anion exchange resin bearing quaternary ammonium functional groups, together with (2) a bile acid buffering amount of a pharmaceutically acceptable alkalizer.
Claim 14
Dependent Claim 110 words
A pharmaceutical composition for the treatment of gastric ulcers in a patient afflicted with pyloric incompetence and concomitant duodenogastric regurgitation of bile acids, and suited for regulating the regurgitation of duodenal contents into the stomach, said composition essentially consisting of a unit dosage formulation of (1) an effective, bile acid conjugating amount of a non-toxic, non-absorbable resinous active agent capable of effectively binding the free and conjugated bile acids present in the stomach as a result of said duodenogastric regurgitation, said resinous active agent being a hydrophobic, styrene-divinyl-benzene copolymer anion exchange resin bearing quaternary ammonium functional groups, together with (2) a bile acid buffering amount of a pharmaceutically acceptable alkalizer.
Claim 15
Dependent Claim 114 words
A pharmaceutical composition for the treatment of gastric ulcers in a patient afflicted with pyloric incompetence and concomitant duodenogastric regurgitation of bile acids, and suited for regulating the regurgitation of duodenal contents into the stomach, said composition essentially consisting of a unit dosage formulation of (1) an effective, bile acid conjugating amount of a non-toxic, non-absorbable resinous active agent capable of effectively binding the free and conjugated bile acids present in the stomach as a result of said duodenogastric regurgitation, said resinous active agent being a hydrophobic, cholestyramine anion exchange resin, together with (2) a bile acid buffering amount of a pharmaceutically acceptable aluminum hydroxide gel alkalizer, and (3) a pharmaceutically effective inert carrier.
Claim 16
Dependent Claim 114 words
A pharmaceutical composition for the treatment of gastric ulcers in a patient afflicted with pyloric incompetence and concomitant duodenogastric regurgitation of bile acids, and suited for regulating the regurgitation of duodenal contents into the stomach, said composition essentially consisting of a unit dosage formulation of (1) an effective, bile acid conjugating amount of a non-toxic, non-absorbable resinous active agent capable of effectively binding the free and conjugated bile acids present in the stomach as a result of said duodenogastric regurgitation, said resinous active agent being a hydrophobic, cholestyramine anion exchange resin, together with (2) a bile acid buffering amount of a pharmaceutically acceptable aluminum hydroxide gel alkalizer, and (3) a pharmaceutically effective inert carrier.
Claim 17
Dependent Claim 40 words
The composition of claim 11, wherein said pharmaceutically acceptable alkalizer is a member selected from the group consisting of sodium bicarbonate, milk of magnesia, calcium carbonate, an aluminum hydroxide gel, a sulphated magnesium hydroxy aluminate, a silicate, and mixtures thereof.
Claim 18
Dependent Claim 19 words
The composition of claim 13, wherein the effective amount of said active agent ranges from 25 to 500 mgs.

References Cited (Backward Citations)

US3007847A Cited
GB914630A Cited
US3499960A Cited
US3624209A Cited
GB1181003A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1984-02-24 1984-08-25 1985-02-24 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1988-02-24 1988-08-25 1989-02-24 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1992-02-24 1992-08-25 1993-02-24 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag